The Secondaries Boom Has a Pricing Problem Nobody Is Talking About

Let's start with the bull case, because it is a real one and I don't want to strawman it. Secondaries funds let LPs sell existing private equity stakes to other buyers, and they let general partners (GPs, the firms that manage the funds and pick the deals) create continuation vehicles (CVs) that move a prized portfolio company into a new fund vehicle instead of selling it outright. The pitch is liquidity. After 2021's overheated dealmaking, buyout funds got stuck holding companies they couldn't sell at the multiples they paid, distributions to LPs dried up, and LPs facing their own cash needs turned to the secondary market to get liquidity without waiting for a traditional exit. Secondaries funds stepped in as buyers, dry powder piled up, and 2026's fundraising numbers reflect real institutional appetite. GP-led volume, where the sponsor itself engineers the liquidity event rather than an LP simply selling its stake to a third party, now makes up 54% of the secondary market mix in the first half of 2026, up from 47% in 2025, according to Campbell Lutyens. The narrative writes itself: private equity solved its liquidity crunch by inventing a new exit route.

Here's where I get off the bus. A GP-led continuation vehicle is a transaction where the general partner sits on both sides of the table. The same firm that manages the original fund and set the asset's carrying value also negotiates the price at which that asset moves into the new vehicle, decides which existing investors roll their stakes forward, and often resets its own carried interest (the performance fee GPs earn, typically 20% of profits above a return hurdle) on a fresh valuation clock. That is not a hypothetical conflict of interest. It is the actual structure of the deal. The SEC's Division of Examinations has flagged exactly this in recent sweeps, focusing on valuation reference-date games, where a GP times the NAV mark used to justify the deal price to a favorable moment, and on information asymmetry between the fund's limited partner advisory committee (LPAC, the small group of LPs who vote to approve conflicted transactions) and the buyers actually pricing the new vehicle. Allens' July 2026 write-up on this is a useful primer on what examiners are actually probing.

The legal system is already catching up. Proskauer's coverage of Delaware Chancery litigation over a continuation vehicle transaction lays out a fact pattern that should worry anyone treating CVs as a plumbing upgrade rather than a conflicted-party transaction. The dispute, following the ADIC v. EMG line of cases, centers on whether the sponsor gave LPs a fair shot at understanding the valuation methodology before asking them to either roll into the new vehicle or cash out at a price the sponsor itself set. Delaware's Court of Chancery does not need many of these cases to change market behavior; a handful of unfavorable rulings on disclosure adequacy will reshape how every GP structures the next CV, and reshape it in the direction of more caution, not less. If you are an LP counting on the current CV market structure staying static while you deploy capital into secondaries funds that hold these assets, that is a bad assumption.

ILPA, the Institutional Limited Partners Association that sets industry norms for LP protections, is not waiting for the courts to sort this out. Its draft new Continuation Vehicle guidance, circulated for industry comment in mid-2026, tightens expectations around independent valuation opinions, LPAC information rights, and timelines for LPs to evaluate a roll-versus-cash decision. When ILPA issues new guidance, it is because the existing norms failed often enough that the largest LPs in the world demanded a fix. That alone tells you the current system has been producing outcomes sophisticated institutional investors did not like.

Now look at the pricing data itself, because it exposes something the fundraising press releases don't. Bain & Company's 2026 Midyear Report, drawing on an ILPA member poll from April 2026, found that more than half of LPs say the most markdown they'll tolerate against a fund's last reported NAV is 5%, and about 1 in 5 LPs are actively cutting their buyout allocations because of liquidity pressure, not conviction. That 5% tolerance line matters enormously against the 8% average discount figure from the Allens-cited research. It means the deals that clear are getting cherry-picked: GPs are only bringing their best, most defensible, most demand-generating assets to the CV market, the "trophy" companies where buyers will pay close to NAV because the growth story is real and visible. Campbell Lutyens' 1H 2026 data confirms this bifurcation in hard numbers. Single-asset continuation vehicles (SACVs), which typically hold one trophy company, saw discounts tighten to just 2.9%. Multi-asset continuation vehicles (MACVs), which bundle several portfolio companies including weaker ones, saw discounts widen to 10.5%. That's not one secondaries market. That's two markets wearing the same label, and the trophy-asset market is the one getting all the press.

Meanwhile, the assets that can't clear at a credible price are piling up. Bain's data shows the implied buyout capital cycle, essentially how long it takes a dollar invested to come back to LPs through exits, has stretched to roughly 7 years, well above historical norms, and most North American and Western European buyout NAV still sits in 2021-or-earlier vintage funds. Translation: there is a large and growing second tier of aging portfolio companies bought at 2021 prices that GPs cannot exit conventionally and cannot bring to the secondary market at a price LPs will accept without a painful markdown. Houlihan Lokey's framing of the $240 billion secondary market, covered by Secondary Scoop, argues this scale changes how everyone should think about NAV itself, because a market this large is now a price-discovery mechanism, not just a relief valve. I'd go further: it's a price-discovery mechanism that's telling you a meaningful chunk of 2021-vintage private equity NAV is marked too high, and the only reason that hasn't shown up as a bigger markdown wave is that the discount-averse assets simply aren't transacting yet.

And the dry powder cushion everyone points to as evidence of a healthy market is thinner than it looks. Secondary-focused dry powder sits around $194 billion to $248 billion depending on whose estimate you use (Evercore's H1 2026 Secondary Market Review versus William Blair's 2026 report), against a capital overhang multiple near 1.0x, meaning roughly one year of deployment capacity. Prior cycles ran with considerably larger cushions. A market with a thin buffer and heavy reliance on continued fundraising momentum is a market where a fundraising slowdown, not a crisis, is enough to expose the pricing gap between what GPs want to mark their aging assets at and what buyers will actually pay. Bain's own report calls this a midyear warning, and Secondary Scoop's coverage of that warning is blunt about LP scrutiny making these deals harder to close, not easier, even as headline fundraising totals climb.

Here's my named risk, stated plainly. If you're an LP or an accredited investor allocating into a secondaries fund today because the fundraising headlines look strong, the specific way this goes wrong is a liquidity mismatch layered on top of a valuation mismatch. You commit capital to a secondaries fund believing it buys diversified, appropriately-discounted stakes across the market. In reality, GP-led supply is now the majority of deal flow, at 54% of the market per Campbell Lutyens, and that supply is bifurcated between trophy assets priced near NAV, where you're not actually getting the discount you think you're paying for, and a growing shadow inventory of aging, hard-to-price assets that GPs are structurally incentivized to avoid marking down honestly until they absolutely have to, because a GP's own carried interest reset depends partly on the valuation used to move the asset into the new vehicle. If ILPA's new guidance or a Delaware Chancery ruling forces more transparent, independent valuations across the market in the next 12 to 18 months, that shadow inventory could reprice all at once. Funds holding concentrated exposure to 2021-vintage MACV-style continuation vehicles, the 10.5% average discount cohort, are the ones most likely to take a mark-to-market hit when that happens. You will not see this risk in a fund's marketing deck. You will see it in the footnotes of a valuation policy, if you know to look.

So what would I actually do here. First, if you're evaluating a secondaries fund manager, ask directly what percentage of their CV exposure is single-asset trophy deals versus multi-asset bundles, and ask for the discount-to-NAV they actually paid on each, not the blended average. A blended number hides exactly the bifurcation that matters. Second, ask whether the manager uses an independent third-party valuation firm for CV pricing decisions, separate from the sponsor GP's own marks, and whether that opinion is shared with the fund's LPAC before the deal closes, not after. ILPA's draft guidance is pushing toward exactly this standard, and a manager who already meets it is lower risk than one waiting for the rule to become mandatory. Third, read the fund's side letter and governance documents for how carried interest is calculated across a continuation vehicle transaction. If the GP resets its carry clock on a rollover asset, that's a direct financial incentive to price the deal favorably to itself, and you want to know the size of that incentive before you commit capital. Fourth, treat any secondaries allocation pitch built primarily around fundraising size or total market volume with skepticism. A $240 billion market and a $5 billion fund close are supply-side facts. They tell you nothing about whether the specific assets a given fund is buying are priced fairly. Ask for the vintage-year breakdown of the fund's target assets instead; heavy concentration in 2021-and-earlier vintages is where the pricing risk lives, per Bain's own data on the 7-year capital cycle.

None of this means the secondaries market is a scam or that continuation vehicles are inherently bad structures. Liquidity has real value, and a well-governed CV with independent pricing and genuine LPAC teeth can be a fair deal for everyone at the table. My argument is narrower and, I think, harder to dismiss: the market is currently pricing a two-tier reality as if it were one uniform asset class, regulators and industry bodies are actively intervening because the current disclosure and valuation practices produced enough bad outcomes to warrant it, and the headline fundraising and volume numbers you're reading in the press are supply-side vanity metrics that tell you nothing about whether you're buying trophy assets at fair discounts or shadow inventory at prices that haven't caught up to reality yet. Do the diligence the fund's marketing materials won't volunteer, or wait for ILPA's guidance and the Delaware litigation to force more transparency before you write the check.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.